Vor Biopharma Statistics
Total Valuation
Vor Biopharma has a market cap or net worth of $128.17 million. The enterprise value is -$72.40 million.
Important Dates
The last earnings date was Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vor Biopharma has 6.85 million shares outstanding. The number of shares has increased by 42.97% in one year.
| Current Share Class | 6.85M |
| Shares Outstanding | 6.85M |
| Shares Change (YoY) | +42.97% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 17.35% |
| Owned by Institutions (%) | 13.91% |
| Float | 4.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.49
| Current Ratio | 3.49 |
| Quick Ratio | 3.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -121.29% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -229.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$10.47M |
| Employee Count | 159 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.72% in the last 52 weeks. The beta is 2.02, so Vor Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.02 |
| 52-Week Price Change | +8.72% |
| 50-Day Moving Average | 31.74 |
| 200-Day Moving Average | 24.81 |
| Relative Strength Index (RSI) | 25.94 |
| Average Volume (20 Days) | 392,398 |
Short Selling Information
The latest short interest is 1.24 million, so 18.04% of the outstanding shares have been sold short.
| Short Interest | 1.24M |
| Short Previous Month | 1.35M |
| Short % of Shares Out | 18.04% |
| Short % of Float | 25.32% |
| Short Ratio (days to cover) | 2.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -336.67M |
| Pretax Income | -1.66B |
| Net Income | -1.66B |
| EBITDA | -332.09M |
| EBIT | -336.67M |
| Earnings Per Share (EPS) | -$342.66 |
Full Income Statement Balance Sheet
The company has $200.57 million in cash and n/a in debt, giving a net cash position of $200.57 million or $29.26 per share.
| Cash & Cash Equivalents | 200.57M |
| Total Debt | n/a |
| Net Cash | 200.57M |
| Net Cash Per Share | $29.26 |
| Equity (Book Value) | -1.51B |
| Book Value Per Share | -239.67 |
| Working Capital | 146.15M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$113.60 million and capital expenditures -$489,000, giving a free cash flow of -$114.09 million.
| Operating Cash Flow | -113.60M |
| Capital Expenditures | -489,000 |
| Free Cash Flow | -114.09M |
| FCF Per Share | -$16.65 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vor Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.97% |
| Shareholder Yield | -42.97% |
| Earnings Yield | -1,298.63% |
| FCF Yield | -89.01% |
Analyst Forecast
The average price target for Vor Biopharma is $84.00, which is 349.20% higher than the current price. The consensus rating is "Buy".
| Price Target | $84.00 |
| Price Target Difference | 349.20% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 19, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 19, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |